CLDX Short Information Celldex Therapeutics Inc.

Twenty Trading Day Totals
Total Shorted Volume	1,102,091
Total Actual Volume	9,088,845

Averages
Average Short Volume	55,105
Average Short Percentage	66.11%

Is there a CLDX Short Squeeze or Breakout about to happen?

See the CLDX Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2022-09-29	28.41	28.35	28.875	27.26	620,769	51,287	33.5650
2022-09-28	28.2	28.79	29.18	27.95	588,312	26,117	37.8162
2022-09-27	28.3	27.81	28.7	27.2	663,300	67,002	38.8174
2022-09-26	27.89	27.67	28.745	27.61	443,423	24,599	42.9947
2022-09-23	28.59	27.98	28.59	27.11	554,155	80,520	78.4742
2022-09-22	28.92	28.78	29.2	28.28	304,821	47,476	87.7074
2022-09-21	30.38	29.02	30.46	28.78	397,593	51,237	78.9294
2022-09-20	29.25	30.06	30.15	28.84	320,625	41,303	68.3576
2022-09-19	28.78	29.49	29.575	28.3	395,457	54,797	62.0507
2022-09-16	29.8	29.25	30.18	28.49	610,131	115,608	90.3908
2022-09-15	30.24	30.31	30.96	29.95	233,786	34,992	74.1859
2022-09-14	30.47	30.48	31.12	29.92	309,851	37,639	81.9112
2022-09-13	30.58	30.27	30.91	29.48	563,696	89,505	84.9435
2022-09-12	31.6	31.58	31.69	30.85	283,970	29,064	73.5202
2022-09-09	31.31	31.58	32.45	31.25	365,848	73,771	71.6662
2022-09-08	29.93	31.03	31.09	29.53	494,572	37,617	56.3264
2022-09-07	28.42	30.18	30.2	28.38	440,420	45,436	74.6811
2022-09-06	29.72	28.6	30.49	28.34	493,547	65,414	72.8409
2022-09-01	30.01	30.66	30.73	29.26	540,020	79,554	55.2098
2022-08-31	30.96	30.4	31.45	30.14	464,549	49,153	57.7774

Stock Information

Celldex Therapeutics Inc. Company Name:

CLDX Stock Symbol:

NASDAQ Market:

Celldex Therapeutics Inc. Website:

Get CLDX Alerts

News, Short Squeeze, Breakout and More Instantly...

CLDX - Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) toda...
CLDX - Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria...
CLDX - Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile- -Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose group at week 12 and 75.1% at week 8 in the 3 mg/kg dose group (reflects one dose; ongoing)- ...